Cathay Biotech Inc.
688065.SS · SHH
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.95 | 11.34 | -6.84 | 0.83 |
| FCF Yield | -0.68% | 0.51% | -0.64% | -0.24% |
| EV / EBITDA | 180.11 | 137.59 | 93.64 | 263.29 |
| Quality | ||||
| ROIC | 0.51% | 0.73% | 0.55% | 0.79% |
| Gross Margin | 36.49% | 27.58% | 33.63% | 16.59% |
| Cash Conversion Ratio | -0.47 | – | 0.64 | – |
| Growth | ||||
| Revenue 3-Year CAGR | 14.88% | 13.42% | 10.09% | 6.61% |
| Free Cash Flow Growth | -246.60% | 190.16% | -253.05% | -133.76% |
| Safety | ||||
| Net Debt / EBITDA | -47.65 | -43.80 | -41.24 | -48.06 |
| Interest Coverage | 137.89 | 246.77 | 23.10 | 30.93 |
| Efficiency | ||||
| Inventory Turnover | 0.43 | 0.56 | 0.44 | 0.52 |
| Cash Conversion Cycle | 53.41 | 30.69 | 25.08 | 19.21 |